We’ve recently updated our valuation analysis.

Celon Pharma Valuation

Is CLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLN?

Other financial metrics that can be useful for relative valuation.

CLN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA172.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CLN's PS Ratio compare to its peers?

The above table shows the PS ratio for CLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average15.4x
BGD Biogened
0.4xn/azł31.9m
RVU Ryvu Therapeutics
20.2x-9.3%zł798.5m
BML BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek
8.7xn/azł443.1m
CBD Cannabis Poland
32.1xn/azł11.7m
CLN Celon Pharma
3.7x5.2%zł704.3m

Price-To-Sales vs Peers: CLN is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (15.4x).


Price to Earnings Ratio vs Industry

How does CLN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.5%
n/an/an/a

Price-To-Sales vs Industry: CLN is good value based on its Price-To-Sales Ratio (3.7x) compared to the European Pharmaceuticals industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is CLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.7x
Fair PS Ratio8.4x

Price-To-Sales vs Fair Ratio: CLN is good value based on its Price-To-Sales Ratio (3.7x) compared to the estimated Fair Price-To-Sales Ratio (8.4x).


Share Price vs Fair Value

What is the Fair Price of CLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLN (PLN13.8) is trading above our estimate of fair value (PLN1.23)

Significantly Below Fair Value: CLN is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł13.80
zł27.55
+99.6%
49.8%zł48.70zł11.00n/a4
Nov ’23zł13.50
zł27.55
+104.1%
49.8%zł48.70zł11.00n/a4
Oct ’23zł13.00
zł30.92
+137.8%
39.6%zł48.70zł11.00n/a5
Sep ’23zł14.36
zł30.92
+115.3%
39.6%zł48.70zł11.00n/a5
Aug ’23zł18.14
zł30.92
+70.5%
39.6%zł48.70zł11.00n/a5
Jul ’23zł15.56
zł32.32
+107.7%
31.2%zł48.70zł18.00n/a5
Jun ’23zł18.84
zł36.12
+91.7%
33.0%zł49.00zł18.00n/a5
May ’23zł22.10
zł40.72
+84.3%
16.9%zł49.00zł32.00n/a5
Apr ’23zł26.25
zł40.72
+55.1%
16.9%zł49.00zł32.00n/a5
Mar ’23zł23.40
zł43.23
+84.8%
18.4%zł49.00zł32.00n/a3
Feb ’23zł29.00
zł43.23
+49.1%
18.4%zł49.00zł32.00n/a3
Jan ’23zł33.15
zł43.23
+30.4%
18.4%zł49.00zł32.00n/a3
Dec ’22zł30.10
zł45.23
+50.3%
21.5%zł55.00zł32.00n/a3
Nov ’22zł36.20
zł45.23
+25.0%
21.5%zł55.00zł32.00zł13.503
Oct ’22zł36.50
zł51.57
+41.3%
13.3%zł57.70zł42.00zł13.003
Sep ’22zł41.40
zł51.57
+24.6%
13.3%zł57.70zł42.00zł14.363
Aug ’22zł38.30
zł51.57
+34.6%
13.3%zł57.70zł42.00zł18.143
Jul ’22zł43.30
zł54.90
+26.8%
17.5%zł65.00zł42.00zł15.563
Jun ’22zł45.95
zł54.97
+19.6%
17.6%zł65.20zł42.00zł18.843
May ’22zł47.50
zł54.07
+13.8%
16.2%zł62.50zł42.00zł22.103
Apr ’22zł49.00
zł50.30
+2.7%
31.9%zł65.20zł28.00zł26.253
Mar ’22zł46.10
zł50.30
+9.1%
31.9%zł65.20zł28.00zł23.403
Feb ’22zł44.80
zł43.97
-1.9%
35.6%zł65.20zł28.00zł29.003
Jan ’22zł40.55
zł38.07
-6.1%
20.9%zł47.50zł28.00zł33.153
Dec ’21zł40.60
zł38.07
-6.2%
20.9%zł47.50zł28.00zł30.103
Nov ’21zł33.60
zł34.98
+4.1%
25.4%zł47.50zł28.00zł36.203

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies